Search
EHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement
On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.
Read moreMutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?
During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.
Read moreCOST Action ‘EuNet-INNOCHRON’
The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.
Read moreSWG Educational Activities
During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.
Read morePublications
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, Lassila R, Leebeek FWG, Makris M, Owaidah T, Sholzberg M, Tiede A, Werring DJ, van der Worp HB,…
EHA, AHA and GBMTA Successfully Conclude the First Joint Virtual Mini Hematology Tutorial
EHA-AHA-GBMTA Mini Hematology Tutorial
November 10-11, 2021
Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof YK Hakobyan (Armenian Hematology Association)
Dr T Kvatchadze (Georgian Association For Blood and Bone Marrow Transplantation)
EHA, the Armenian Hematology Association (AHA) and for the first time with the Georgian…
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Read more